Literature DB >> 22826033

Guidelines for the quality control of population pharmacokinetic-pharmacodynamic analyses: an industry perspective.

P L Bonate1, A Strougo, A Desai, M Roy, A Yassen, J S van der Walt, A Kaibara, S Tannenbaum.   

Abstract

Quality population modeling and simulation analyses and reports are something every modeler desires. However, little attention in the literature has been paid to what constitutes quality regarding population analyses. Very rarely do published manuscripts contain any statement about quality assurance of the modeling results contained therein. The purpose of this manuscript is to present guidelines for the quality assurance of population analyses, particularly with regards to the use of NONMEM from an industrial perspective. Quality guidelines are developed for the NONMEM installation itself, NONMEM data sets, control streams, output listings, output data files and resultant post-processing, reporting of results, and the review processes. These guidelines were developed to be thorough yet practical, though are not meant to be completely comprehensive. It is our desire to ensure that what is reported accurately reflects the collected data, the modeling process, and model outputs for a modeling project.

Mesh:

Year:  2012        PMID: 22826033      PMCID: PMC3475847          DOI: 10.1208/s12248-012-9387-9

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  5 in total

1.  Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children.

Authors:  C Chen
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

2.  Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM.

Authors:  Ron J Keizer; Michel van Benten; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Journal:  Comput Methods Programs Biomed       Date:  2010-06-02       Impact factor: 5.428

3.  A population pharmacokinetic model for docetaxel (Taxotere): model building and validation.

Authors:  R Bruno; N Vivier; J C Vergniol; S L De Phillips; G Montay; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1996-04

4.  Validation of simple and complex models in physiology and medicine.

Authors:  C Cobelli; E R Carson; L Finkelstein; M S Leaning
Journal:  Am J Physiol       Date:  1984-02

5.  Population pharmacokinetics of clinafloxacin in healthy volunteers and patients with infections: experience with heterogeneous pharmacokinetic data.

Authors:  B Frame; J Koup; R Miller; R Lalonde
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

  5 in total
  13 in total

Review 1.  Reproducible pharmacokinetics.

Authors:  John P A Ioannidis
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-19       Impact factor: 2.745

Review 2.  Enhancing population pharmacokinetic modeling efficiency and quality using an integrated workflow.

Authors:  Henning Schmidt; Andrijana Radivojevic
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-07-24       Impact factor: 2.745

3.  Population Pharmacokinetic Model of Oxfendazole and Metabolites in Healthy Adults following Single Ascending Doses.

Authors:  Thanh Bach; Daryl J Murry; Larissa V Stebounova; Gregory Deye; Patricia Winokur; Guohua An
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

4.  Evaluation of Assumptions Underpinning Pharmacometric Models.

Authors:  Qing-Xi Ooi; Daniel F B Wright; Geoffrey K Isbister; Stephen B Duffull
Journal:  AAPS J       Date:  2019-08-05       Impact factor: 4.009

5.  Dose Optimization of Cefpirome Based on Population Pharmacokinetics and Target Attainment during Extracorporeal Membrane Oxygenation.

Authors:  Jin Wi; Min Jung Chang; Soyoung Kang; June Young Jang; Jongsung Hahn; Dasohm Kim; Jun Yeong Lee; Kyoung Lok Min; Seungwon Yang
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

6.  Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.

Authors:  S F Marshall; R Burghaus; V Cosson; S Y A Cheung; M Chenel; O DellaPasqua; N Frey; B Hamrén; L Harnisch; F Ivanow; T Kerbusch; J Lippert; P A Milligan; S Rohou; A Staab; J L Steimer; C Tornøe; S A G Visser
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-03-14

7.  Reporting guidelines for population pharmacokinetic analyses.

Authors:  Kevin Dykstra; Nitin Mehrotra; Christoffer Wenzel Tornøe; Helen Kastrissios; Bela Patel; Nidal Al-Huniti; Pravin Jadhav; Yaning Wang; Wonkyung Byon
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-04-30       Impact factor: 2.745

8.  Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib.

Authors:  Ana Ruiz-Garcia; Weiwei Tan; Jerry Li; May Haughey; Joanna Masters; Jennifer Hibma; Swan Lin
Journal:  Pharmaceutics       Date:  2020-04-07       Impact factor: 6.321

9.  Establishing Good Practices for Exposure-Response Analysis of Clinical Endpoints in Drug Development.

Authors:  R V Overgaard; S H Ingwersen; C W Tornøe
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-09-22

10.  Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network.

Authors:  Lourdes Cucurull-Sanchez; Michael J Chappell; Vijayalakshmi Chelliah; S Y Amy Cheung; Gianne Derks; Mark Penney; Alex Phipps; Rahuman S Malik-Sheriff; Jon Timmis; Marcus J Tindall; Piet H van der Graaf; Paolo Vicini; James W T Yates
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.